1 Sarah Cannon Research Institute (SCRI).
2 Northern Illinois University.
* Corresponding Author
World Journal of Advanced Research and Reviews, 2020, 08(01), 358–364
Article DOI: 10.30574/wjarr.2020.8.1.0389
Received on 15 September 2020; revised on 22 October 2020; accepted on 28 October 2020
Background: Laboratory results are frequent safety observations, but a value outside a reference interval is not itself a complete description of clinical severity. Reproducible reporting requires a versioned grading reference, explicit time-
window rules, and a traceable path from analysis records to participant summaries.
Objective: To describe a practical workflow for laboratory toxicity outputs aligned with the directional toxicity approach in CDISC ADaM Implementation Guide (ADaMIG) v1.2 and the term-specific criteria in National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Methods: This focused narrative review synthesizes the CTCAE v5.0 reference, ADaMIG v1.2, clinical-trial reporting
guidance, and selected methodological literature available by 31 December 2020. A synthetic serum-sodium example
illustrates directional grading, treatment-emergent selection, an analysis listing, and participant-level summary counts.
No participant data or empirical performance results were used.
Results: The proposed workflow separates lower- and higher-direction grades for parameters with bidirectional toxicity, retains record-level evidence in a listing, and summarizes each participant’s maximum eligible grade by analyte anddirection. The example applies a protocol-defined postbaseline window through 30 days after last dose and uses an
analyte-specific evaluable denominator; both are illustrative conventions requiring study-level specification.
Conclusion: A reviewable laboratory toxicity output depends on harmonized units and reference limits, explicit grade
criteria and boundary handling, documented treatment-emergent and follow-up rules, and reconciliation between
subject-level records and summary counts. ADaMIG variable names can support implementation, while study
metadata and specifications determine the final analysis dataset.
CTCAE, Laboratory Toxicity, CTCAE v5.0; ADaMIG v1.2; ADaM; Clinical Trial Safety; Synthetic Data; Analysis Dataset; Clinical Programming, Safety Reporting, Laboratory Abnormalities
Preview Article PDF
Jyoti (Jo) Agarwal and Neetika Khurana. BIDIRECTIONAL LABORATORY TOXICITY REPORTING USING CTCAE V5.0 AND ADAMIG V1.2. World Journal of Advanced Research and Reviews, 2020, 08(01), 358–364. Article DOI: https://doi.org/10.30574/wjarr.2020.8.1.0389